Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 21, Issue 12, Pages 1600-1603Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458514567728
Keywords
Multiple sclerosis; natalizumab; John Cunningham Virus (JCV); progressive multifocal leukoencephalopathy (PML)
Categories
Funding
- Biogen Idec
Ask authors/readers for more resources
The presence of anti-John Cunningham Virus (JCV) antibodies is a risk factor for the development of progressive multifocal leukoencephalopathy (PML) in MS patients treated with natalizumab. It has been suggested that an increase in serum anti-JCV antibody index precedes the development of PML. We here describe extensive longitudinal serum anti-JCV antibody indexes of four MS patients who developed PML. Anti-JCV antibodies were measured using the STRATIFY JCVDxSelect test. All four patients had rather stable high anti-JCV antibody indexes in all samples obtained before developing PML. Possibly caused by reaching the saturation level of the assay, no increase in anti-JCV antibody indexes was seen just before the diagnosis of PML. This study confirms that high serum anti-JCV antibody indexes precede natalizumab-associated PML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available